Viewing nowCombinationEmpagliflozin/Metformin Extended-Release Tablets 25/1000 mg
Empagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202501759 · Approved 2025.07.11 · Insurance code 643508930
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adult patients with type 2 diabetes through the combined use of empagliflozin and metformin. It can enhance treatment effectiveness when used in conjunction with a dietary and exercise regimen. Careful use is also necessary for type 2 diabetes patients with cardiovascular disease whose blood sugar is inadequately controlled. This medication is expected to have a positive effect on blood sugar control and cardiovascular risk management, making it useful for the treatment of type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. This medicine should be taken with a meal once daily in the evening to reduce gastrointestinal adverse reactions caused by metformin. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the initial recommended dose is a total daily dose of empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this medicine from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate the medicine well and do not have other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age or older, renal function and the risk of volume depletion should be considered.
This medication helps regulate blood sugar levels. However, during the use of this medication, there is a risk of a rare complication called lactic acidosis, which warrants caution. Lactic acidosis is a serious condition caused by excessive accumulation of lactic acid in the body, with symptoms including fatigue, muscle pain, difficulty breathing, and abdominal pain. Additionally, this medication may increase the risk of hypoglycemia when taken together with insulin or sulfonylureas, so blood sugar changes should be monitored closely. Patients with impaired kidney function, acute renal failure, dehydration, severe infections, or heart failure should not take this medication. Use of iodine contrast agents requires temporary discontinuation of this medication before and after the tests, and resumption should only occur after normal kidney function is confirmed. Women who are pregnant or may become pregnant are advised against taking this medication, and it should also be avoided during breastfeeding. This medication may increase the risk of genital and urinary tract infections; therefore, if infection symptoms appear, patients should consult their doctor immediately. Elderly patients or those at risk for fluid loss should be aware of dehydration and hypotension and undergo regular kidney function checks. It is advisable to avoid alcohol consumption during treatment and to watch for hypoglycemia after sudden dietary imbalances or intense physical activities. Patients taking this medication should report any unusual symptoms to healthcare professionals immediately and undergo appropriate examinations. The tablets should be swallowed whole without breaking or chewing, and it is normal for the tablet coating to appear in the stool. This medication may interact with other drugs, so if patients are taking any other medications, they must inform their doctor or pharmacist.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is recommended to store the medication at room temperature, between 1 to 30 degrees Celsius, avoiding excessively hot or cold conditions.
Brownish-red oval extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.